ISOPLEXIS Branford, Connecticut
Which therapies work best for the patients who urgently need them? Branford-based IsoPlexis has developed a platform that delivers these critical answers. Featured in more than 70 peer-reviewed scientific publications and with versatility demonstrated across a wide range of research areas, including cancer immunology, infectious disease, cellular and regenerative medicine, inflammation and neurology, and oncology, the company’s technology isolates single immune cells and analyzes their complete extracellular functional response, enabling doctors to develop more effective treatments for cancer and other diseases. IsoPlexis’s groundbreaking single-cell platform was developed by scientific leaders at Yale and Caltech; leaders at UCLA and Memorial Sloan Kettering Cancer Center have further applied it to their clinical analyses.
- $2.6 million equity investment from the Eli Whitney Fund
- $2.3 million SSBCI investment
- $1.1 million CBIF investment
- $100,000 SBIR grant
- $35,000 intern grant
- CI’s Dan Wagner joined the IsoPlexis board
- Help finding lab facilities and key team members
- Press release coordination
Today, leading academic labs and pharmaceutical companies use the IsoPlexis platform to improve the way they treat disease. Through partnerships with organizations including Yale, Caltech, UCLA, Kite Pharma and others, IsoPlexis is helping to advance groundbreaking research and therapeutic development in infectious disease, cancer immunology, cell and gene therapy, inflammation and other emerging areas. The company has raised multiple rounds of funding totaling nearly $70 million in concert with North Pond Ventures, North Sound, Spring Mountain Capital and other institutional investors. IsoPlexis has also been awarded $19 million in small-business research grants from the National Institutes of Health. The company has 125 full-time employees.